PharmaSentinel Partners with Pay10 for Medsii.com Expansion

May 13, 2025
PharmaSentinel Limited has announced a license agreement with Pay10 for its AI-driven platform Medsii.com, enhancing healthcare analytics capabilities.

PharmaSentinel Limited has announced a significant license agreement with Pay10 for its flagship product, Medsii.com, announced in a press release. This partnership allows PharmaSentinel to further develop its AI-driven digital health solutions, while enabling Pay10 to enhance its intelligence services.

Medsii.com is a B2B platform that leverages AI to provide comprehensive scientific, clinical, regulatory, and competitive intelligence. This collaboration is expected to help PharmaSentinel capitalize on the growing healthcare analytics market, which is expanding at a 20% CAGR.

The agreement will also allow Pay10 to offer enhanced insights and regulatory support to its global users, driving innovation and improving data accessibility for stakeholders worldwide. Terms of the agreement remain confidential.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.